Loading...
|
Please use this identifier to cite or link to this item:
http://ir.ncue.edu.tw/ir/handle/987654321/13220
|
| Title: | Synergistic Effect of Combined Etodolac Plus 5-Fluorouracil in Human Hepatoma Therapy--an In vitro Evaluation by Cell Lines HepG2, HA22T and KELFIB |
| Authors: | Hsieh, Chiu-Lan;Peng, Chiung-Huei;Hsiao, George T.;Wang, Hui-Er;Ko, Wan-Shen;Peng , Robert Y. |
| Contributors: | 生物技術研究所 |
| Keywords: | Hepatoma;COX-2 inhibitor etodolac;5-FU;Chemotherapy |
| Date: | 2007
|
| Issue Date: | 2012-08-07T06:57:23Z
|
| Publisher: | Medwell |
| Abstract: | Hepatocellular Cancer Cell (HCC) lines HepG2, HA22T and KEL FIB were used to test the therapeutic effect of different combined protocols for etodolac plus 5-FU: 1). the selective COX 2 inhibitor etodolac alone at 0.0~0.16 �g �L 1; 2). 5-FU alone at 0.0~1.25 �g mL 1; 3). etodolac (0.31 �g �L 1) plus 5-FU (1.25 �g mL 1) in a simultaneous-, or an alternative sequential protocol. Cell viability was measured using MTT assay and flow cytometric analysis. An inverse dose dependent survival rate was observed for both drugs, while the apoptotic data of the three HCC cell lines have favored the simultaneous administration of etodolac plus 5-FU, which revealed to be more effective than administering etodolac or 5-FU alone. We conclude that in view of the therapeutic efficacy with a minimized cytotoxicity, a simultaneous administration of etodolac plus 5-FU, each at much more reduced dosages than usually prescribed alone, could be strongly recommended for treatment of HCC. |
| Relation: | Research Journal of Biological Sciences, 2(3): 268-279 |
| Appears in Collections: | [生物技術研究所] 期刊論文
|
Files in This Item:
| File |
Size | Format | |
|---|
| index.html | 0Kb | HTML | 606 | View/Open |
|
All items in NCUEIR are protected by copyright, with all rights reserved.
|
